【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人。

治療神經痛 Depression; nocturnal enuresis.

Imipramine hydrochloride belongs to the dibenzazepine group of compounds. The precise mechanism of action is unknown, however, it is postulated that it blocks the uptake of norepinephrine at the nerve endings.

[Absorption]
Bioavailability: 94% to 96%
Effects of Food: None

[Distribution]
Protein Binding: 89%

[Metabolism]
Metabolism sites: Liver, extensive

[Excretion]
Metabolites are excreted in urine.

[Elimination Half Life]
6 to 18 hours

Coadministration with a MAOI or use within 14 days of discontinuing a MAOI.
Hypersensitivity to imipramine hydrochloride or other dibenzazepines.
Myocardial infarction, during the acute recovery period.

C [AUS]

Infant risk cannot be ruled out. [MDX]

[Endocrine metabolic] Weight gain
[Gastrointestinal] Bloating symptom, constipation, xerostomia
[Neurologic] Asthenia, dizziness, headache, somnolence
[Ophthalmic] Blurred vision
[Renal] Urinary retention
[Other] Fatigue

[Depression]
(Hospitalized patients) 100 mg PO per day in divided doses; may increase up to a MAX of 300 mg/day
(Outpatients) 75 mg PO per day; may increase up to a MAX of 200 mg/day; usual maintenance dose, 50 to 150 mg/day

[General principle] Safety and effectiveness in children with nocturnal enuresis below 6 y/o have not been established;
effectiveness in pediatric patients for any other condition has not been established.

[Nocturnal enuresis]
(children 6-12 y/o) initial, 25 mg PO 1 h before bedtime, may increase in 25 mg increments to MAX dose of 50 mg/d or 2.5 mg/kg/d
(children over 12 y/o) initial, 25 mg PO 1 h before bedtime, may increase in 25 mg increments to MAX dose of 75 mg/d or 2.5 mg/kg/d

Nil.

Nil.

Store between 15 to 30 degrees C.